CLAIMS

What is claimed is:

1. A method for treating or preventing a tumor necrosis factor-mediated disease in an individual in need thereof comprising co-administering a tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent to the individual, in therapeutically effective amounts.

2. A method of Claim 1 wherein the tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent are administered simultaneously.

3. A method of Claim 1 wherein the tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent are administered sequentially.

4. A method of Claim 1 wherein the tumor necrosis factor-mediated disease is selected from the group consisting of: autoimmune disease, acute or chronic immune disease, inflammatory disease and neurodegenerative disease.

5. A method of Claim 4 wherein the CD4+ T cell inhibiting agent is cyclosporin or analog thereof.

6. A method of Claim 5 wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or fragment thereof.

7. A method of Claim 6 wherein the antibody is a chimeric antibody.

8. A method of Claim 5 wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.

9. A method of Claim 8 wherein the receptor molecule is a tumor necrosis factor receptor/immunoglobulin G fusion protein.

10. A method of Claim 5 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis release or its action on target cells.

11. A method of Claim 10 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.

12. A method of Claim 11 wherein the phosphodiesterase inhibitor is pentoxifylline.

13. A method of Claim 10 wherein the tumor necrosis factor antagonist is thalidomide.

14. A method of Claim 1 wherein an anti-inflammatory agent is administered in conjunction with the CD4+ T cell inhibiting agent and the tumor necrosis factor antagonist.

15. A method for treating or preventing rheumatoid arthritis in an individual in need thereof comprising administering to the individual cyclosporin or analog thereof in combination with a tumor necrosis factor antagonist, in therapeutically effective amounts.

16. A method of Claim 15 wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or fragment thereof.

17. A method of Claim 16 wherein the antibody is a chimeric antibody.

18. A method of Claim 15 wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.

19. A method of Claim 18 wherein the receptor molecule is a tumor necrosis factor receptor/immunoglobulin G fusion protein.

20. A method of Claim 15 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.

21. A method of Claim 20 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.

22. A method of Claim 21 wherein the phosphodiesterase inhibitor is pentoxifylline.

23. A method for treating or preventing Crohn's disease in an individual in need thereof comprising administering to the individual cyclosporin or analog thereof in combination with a tumor necrosis factor antagonist, in therapeutically effective amounts.

24. A method of Claim 23 wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or fragment thereof.

25. A method of Claim 24 wherein the antibody is a chimeric antibody.

26. A method of Claim 23 wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.

27. A method of Claim 26 wherein the receptor molecule is a tumor necrosis factor receptor/immunoglobulin G fusion protein.

28. A method of Claim 23 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.

29. A method of Claim 28 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.

30. A method of Claim 29 wherein the phosphodiesterase inhibitor is pentoxifylline.

31. A method for treating or preventing acute or chronic immune disease associated with a transplantation in an individual comprising administering to the individual cyclosporin or analog thereof in combination with a tumor necrosis factor antagonist, in therapeutically effective amounts.

32. A method of Claim 31 wherein the transplantation is selected from the group consisting of: renal transplantation, cardiac transplantation, bone marrow transplantation, liver transplantation, pancreatic transplantation, small intestine transplantation, skin transplantation and lung transplantation.

33. A method of Claim 31 wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or fragment thereof.

34. A method of Claim 33 wherein the antibody is a chimeric antibody.

35. A method of Claim 31 wherein the tumor necrosis factor antagonist is a receptor molecule which binds to tumor necrosis factor.

36. A method of Claim 35 wherein the receptor molecule is a tumor necrosis factor/immunoglobulin G fusion protein.

37. A method of Claim 33 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.

38. A method of Claim 37 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor.

39. A method of Claim 38 wherein the phosphodiesterase inhibitor is pentoxifylline.

40. A composition comprising a tumor necrosis factor antagonist and a CD4+ T cell inhibiting agent.

41. A composition of Claim 40 wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or fragment thereof.

42. A composition of Claim 41 wherein the antibody is a chimeric antibody and the CD4+ T cell inhibiting agent is cyclosporin or an analog thereof.

43. A composition of Claim 40 wherein the tumor necrosis factor antagonist prevents or inhibits tumor necrosis factor synthesis, tumor necrosis factor release or its action on target cells.

44. A composition of Claim 43 wherein the tumor necrosis factor antagonist is a phosphodiesterase inhibitor and the CD4+ T cell inhibiting agent is cyclosporin or an analog thereof.

45. A composition of Claim 44 wherein the phosphodiesterase inhibitor is pentoxifylline.